Eighty percent of patients did not fall into the groups and were at considerably lower risk of serious bleeding.

FORBES: Eli Lilly's Big Battle

Even if the bleeding risk is lower than 5%, it could easily be too much of a risk for many doctors.

FORBES: Assessing Avastin's Risk

The trial, widely known as the CRASH-2 trial, published in the Lancet, showed the drug could lower the risk of trauma victims bleeding to death by up to 30 per cent.

FORBES: Why We Want Markets In Health Care